is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM ...

Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain.

Pfizer (NYSE:PFE) announced its intention to sell its entire residual shareholding in Haleon plc, reflecting a divestment ...

In the latest trading session, Pfizer (PFE) closed at $26.64, marking a +1.29% move from the previous day. The stock exceeded the ... The company's earnings per share (EPS) are projected to ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 90% based on the firm’s underlying fundamentals and the stock’s valuation.

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen ...

Pfizer (PFE) stock is lower in Tuesday's session even ... What's more, the company swung to a net profit of $1.06 per share from a loss of 17 cents per share in the year-ago period.

1 Day PFE -0.53% DJIA 1.42% S&P 500 1.76% Health Care/Life Sciences 0.13% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

The the stock of drugmaker has ... compared to the year-ago quarter. PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.97 per share and revenue of $63.2 billion.